Bharat Biotech's pre-submission meeting for Covaxin EUL with WHO on June 23
In a major boost for Bharat Biotech, the World health Organisation (WHO) has accepted its Expression of Interest (EoI) for Covid-19 vaccine Covaxin and scheduled a pre-submission meeting on June 23. Though the meeting will not be a detailed review on the product, the vaccine maker will have an opportunity to submit a summary on overall quality of the jab, according to the WHO.
The information was provided in the WHO website in the Status of COVID-19 Vaccines within WHO EUL-PQ evaluation process document.
Bharat Biotech had said last month that it expects approval for its COVID-19 vaccine Covaxin from the World Health Organisation for Emergency Use Listing (EUL) during July-September.
As per WHO guidelines, Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.
According to WHO, pre-submission meetings provide an opportunity for advice and guidance before submission of a medicines dossier, as well as an opportunity for the applicant to meet WHO medicine assessors who will be involved in assessing their product.
"The pre-submission meeting does not include a detailed review of data or full study reports.However, an essential aspect of the meeting is the submission (at least two weeks in advance of the pre-submission meeting) of a completed QOS-PD (Quality overall summary product dossiers)," WHO said, explaining the process of pre-submission meeting.
Sources had earlier indicated that Bharat Biotech International Limited (BBIL) has conveyed to the Centre that it has already submitted 90 per cent of documents toWHOfor obtaining EUL forCovaxin.
The remaining documents are expected to be submitted by June, the city-based vaccine maker had told the Central government during a discussion last month on obtaining theWHO's authorisation for EUL forCovaxin.
ALSO READ | AIIMS Delhi to start Covaxin trial for children aged 6-12 from today
ALSO READ | Covaxin's phase 3 results soons, says Bharat Biotech
